| Intervention | Outcome | N studies; N subjectsa | Results Effect Size (95% CI)b | Strength of Evidence |
|---|---|---|---|---|
| ACA vs. NTX | Return to any drinking | 3; 800 | RD: 0.02 (-0.03 to 0.08) | Moderate |
| Return to heavy drinking | 4; 1,141 | RD: 0.01 (-0.05 to 0.06) | Moderate | |
| Percentage drinking days | 2; 720 | WMD: -2.98 (-13.4 to 7.5) | Low |
ACA = acamprosate; CI = confidence interval; N = number; NTX = naltrexone; RD = risk difference; WMD = weighted mean difference.
Note: Table only includes comparisons of medications with evidence of efficacy (as determined in KQ 1) and with sufficient data for synthesis. We did not include rows in this table for outcomes that we graded as having insufficient SOE (percentage heavy drinking days, drinks per drinking day, accidents or injuries, quality of life or function, and mortality).
Includes only studies rated as low or medium risk of bias included in the main analyses; these numbers do not include studies rated as high or unclear risk of bias that were included in sensitivity analyses.
Negative effect sizes favor acamprosate over naltrexone.
From: Discussion
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.